Efter stora förändringar av både värdena på portföljinnehaven såväl som själva portföljen lägger Nor...
Vow published its H2 22 report this morning, with the numbers securing record FY revenue (landbased ...
Redeye updates its estimates following Freemelt’s Q4 report, which came in lower than expected due t...
Another impressive quarter in Norway Denmark is also gaining momentum Growth initiatives hurt profit...
Redeye comments on BioInvent's Q4 report. The most significant development in the period is the init...
Redeye is excited to hear that Impact Coatings and Plug Power have signed an LoI for a supply or fra...
Atria ended a volatile 2022 with a strong Q4 that came in well above our expectations on adjusted EB...
Raketech reported solid Q4 results, with revenue of EUR 17.
Redeye returns with a research update following the Q4 report and recent progress in the company.
Redeye comments on Cereno Scientific’s Q4 2022 report.
12% (pre-Q4) dilutive EPS impact, ND from EUR 30m to 15m Alleviates gearing concerns until earnings ...
AcouSort publicerade den 22 februari 2023 bolagets delårsrapport för Q4-22.
Nettoomsättningen inkom något lägre än vad vi estimerat för Q4’22.
Transfer Group publicerade den 22 februari 2023 bolagets delårsrapport för fjärde kvartalet år 2022.
I dag offentliggjorde Risk Intelligence sin delårsrapport för det fjärde kvartalet 2022.
NOSIUM har idag publicerat bolagets delårsrapport för fjärde kvartalet 2022.
Sales -3% and adj. EBITA -8% vs. ABGSC SolidEngineer and earn-out revaluations affect reported resul...
Redeye comments on Isofol Medical’s Q4 2022 report after shareholders voted against the board’s prop...
Redeye comments on Scandion Oncology’s Q4 2022 report, with a new CEO in place and two study readout...
Eurocons rapport för fjärde kvartalet kom in starkare än vi förväntat oss på alla punkter.
